Last updated: July 29, 2026
Peptides for cats follow a different pattern than in dogs. Where dog owners almost always arrive with a mobility problem, cat owners overwhelmingly arrive with a gut problem — inflammatory bowel disease, chronic diarrhoea, vomiting that no diet trial has fixed. BPC-157 is the peptide they end up reading about, because gut mucosa is the tissue it was originally characterised on.
Cats are not small dogs, and the differences matter more than the dose arithmetic suggests. This guide covers what is used, how to dose an animal that weighs four kilos, the chronic kidney disease question, and where copper-based peptides need extra thought.
Quick Answer: Peptides in Cats
- IBD is the number one use. BPC-157 at 5–7 mcg/kg daily for 6–8 weeks is the most commonly reported protocol, with many cats improving inside 2–3 weeks.
- Dosing precision is the real constraint, not the dose itself. A 4 kg cat needs roughly 20–28 mcg — dilute heavily so that is a measurable volume.
- Cats are more sensitive to medication than dogs. Start at the low end and adjust upward, never the reverse.
- Chronic kidney disease is common in older cats and BPC-157 has not been studied in compromised kidneys. This is a genuine unknown, not a theoretical one.
- GHK-Cu needs more caution in cats than in dogs because copper clearance depends on liver function.
- Oral dosing is often the right call for gut conditions — and it sidesteps the problem of injecting a cat daily for eight weeks.
Why Cats Are Different
Three things separate feline peptide use from canine.
Size. A typical cat weighs 3–6 kg. At 5 mcg/kg that is a 15–30 mcg dose. Reconstitute a 10 mg vial with 2 ml of bacteriostatic water and you are trying to draw 0.004 ml — not measurable on any syringe an owner has. The fix is dilution, not a smaller syringe, and it is the single most common practical error.
Metabolic sensitivity. Cats have well-known limitations in glucuronidation and are more sensitive to a range of drugs than dogs are. There is no specific evidence that this applies to peptides, which are cleared by peptidases rather than hepatic conjugation, but it is the reason feline protocols conventionally start low.
Comorbidity profile. Chronic kidney disease is very common in older cats. Since the population most likely to be offered peptides is exactly the older, chronically unwell population, the overlap is not incidental.
BPC-157 for Cats
BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice. It protects and rebuilds gut mucosa, drives angiogenesis and reduces inflammation — a combination that maps closely onto what a cat with IBD needs.
Reported uses in cats, roughly in order of frequency:
- Inflammatory bowel disease — the dominant use. Commonly reported at 5–7 mcg/kg daily for six to eight weeks, with improvement often visible within two to three weeks.
- Chronic diarrhoea — typically 5 mcg/kg daily for four to six weeks.
- Gastric ulceration and reflux — the indication closest to the peptide's original characterisation.
- Stomatitis — feline chronic gingivostomatitis is painful, difficult to treat and often ends in full-mouth extraction. Peptide use here is anecdotal but the mucosal-healing rationale is the same.
- Post-surgical and wound healing — same rationale as in dogs.
KPV for Cats
KPV — the lysine-proline-valine fragment of alpha-MSH — deserves more attention in cats than it currently gets. It inhibits NF-kB directly, it is stable in the gastrointestinal environment, and it is absorbed via PepT1 transporters that upregulate in inflamed intestinal tissue.
For a cat with IBD that means two useful properties: it survives oral administration, which avoids injecting a difficult patient every day for two months, and its uptake increases at precisely the inflamed sites you are targeting. Evidence comes from mouse colitis models; no feline trials have been published.
Thymosin Alpha-1 for Cats
Thymosin Alpha-1 is a thymic peptide that modulates T-lymphocyte function, stimulates interferon-gamma production and supports NK cell activity. It is sold in more than 30 countries as a human medicine under the brand name Zadaxin, and in veterinary contexts it has been used to improve immune response to viral disease.
In cats it comes up around chronic viral and immune-mediated conditions and in convalescence. It is worth being clear about what it is not: it is not a treatment for feline infectious peritonitis. FIP is treated with antivirals — GS-441524 being the well-known one, on which the FDA has published a formal position regarding compounded use. Thymosin Alpha-1 is sometimes discussed as supportive care alongside that, not as a substitute for it.
Dosing by Cat Weight
Feline dosing sits at 2–7 mcg/kg/day in reported use, lower than the ceiling used in dogs. Start at the bottom.
Course length in reported feline protocols is six to eight weeks for IBD and four to six for chronic diarrhoea, then stop and reassess. Many cats that respond do so inside the first three weeks.
The Chronic Kidney Disease Question
This deserves its own section because it comes up constantly and is usually answered too confidently in both directions.
BPC-157 shows protective effects on kidney tissue in rodent models, particularly against medication-induced damage. That research was conducted on healthy kidneys. How the peptide behaves in an animal whose renal function is already compromised has not been studied, and extrapolating a protective effect in healthy tissue to a therapeutic effect in diseased tissue is not sound reasoning.
The practical position: CKD is not an established contraindication, but it is not established as safe either. In a cat with diagnosed kidney disease this is a conversation to have with your vet, ideally one who will monitor renal values through the course rather than assume.
Giving Peptides to a Cat
The practical obstacle in cats is not pharmacology, it is compliance. An eight-week daily injection course is a lot to ask of a cat and its owner.
Oral is therefore the preferred route wherever the target is the gut, which covers most feline use. It can be given in food, though palatability varies and some cats detect it.
Subcutaneous injection uses the scruff, the same site owners of CKD cats already use for fluids. Volumes are tiny — well under 0.1 ml — so a U-100 insulin syringe is essential. Rotate sites and keep the reconstituted vial refrigerated.
Stomatitis: The Hardest Case
Feline chronic gingivostomatitis deserves separate mention because it is the condition where owners are most desperate and the conventional options are least appealing. It is intensely painful, poorly understood, and the treatment that works most reliably is full-mouth extraction. Many cats do well after that surgery, but it is an irreversible decision that owners understandably want to avoid.
The rationale for peptides here is mucosal: BPC-157's best-characterised action is protection and repair of mucosal tissue, and oral mucosa is mucosa. KPV's direct NF-kB inhibition addresses the inflammatory component. Both arguments are mechanistic rather than evidential — there are no published feline stomatitis trials for either compound, and reports are anecdotal.
What is worth saying plainly is that a cat in stomatitis pain should not have definitive treatment delayed while a six-week peptide course is attempted. If extraction is indicated, the peptide question is one of adjunct and post-operative healing, not alternative.
How to Tell Whether It Is Working
Cats hide illness well, and the improvements peptide protocols target are gradual. Track something concrete from before you start.
- Weight, weekly, on the same scale. In a cat with IBD this is the single most informative number. Kitchen scales work; consistency matters more than precision.
- Faecal score using a standard chart rather than description, recorded daily. This is what responds first in most gut protocols.
- Vomiting frequency as a simple tally per week.
- Appetite and food volume actually consumed, not offered.
- Grooming and coat condition. A cat that resumes grooming is usually a cat that feels better; a matted coat is often the first sign that it does not.
If nothing has shifted by week six, continuing is unlikely to change the outcome, and the possibility that the underlying diagnosis is wrong deserves revisiting — particularly in an older cat, where intestinal lymphoma presents very much like IBD.
Safety, Cost and Sourcing
No peptide discussed here is approved for use in cats, and the evidence base is thinner than for dogs simply because fewer owners try it. The angiogenesis caution applies as it does in every species: BPC-157 promotes blood vessel formation, so an animal with a known or suspected tumour is not a good candidate. Older cats presenting with weight loss and GI signs should have those signs worked up before being treated, since intestinal lymphoma can look a great deal like IBD.
Cost is the one area where cats are easier. Because dosing is weight-based, a 4 kg cat consumes a fraction of what a large dog does — a single 5 mg vial can cover a full eight-week course with room to spare, putting a typical course well under $50 in peptide cost.
Sourcing follows the same rules as everywhere else: a compounding pharmacy via your veterinarian is the better route where available, and research-grade vendors that publish third-party certificates of analysis are the realistic alternative. See the peptides for animals overview for the 2026 regulatory picture, including the FDA advisory committee's July 2026 vote on compounded BPC-157 and KPV.
Dog owners should read peptides for dogs, where the use case is mobility rather than gut. Horse owners should start with peptides for horses.
